As more data accumulates from COVIDpos and COVIDneg patients in the coming months, these analyses need to be expanded to assess similarities and differences in the temporal trends of laboratory test results among a wider range of patient subgroups relevant for COVID-19 outcomes, such as those who have pre-existing conditions (e.g. diabetes, hypertension, obesity, malignancies) or patients who are on specific medication (e.g. ACE inhibitors, statins, immunosuppressants). This evidence concerns the gene ACE and diabetes mellitus.